Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renal Effects of Three Contrast Media in At-Risk Patients
NCT00335101Phase 4Withdrawn
- Sponsor
- GE HealthCare
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial of iodixanol in coronary artery disease (CAD) (3 arms), sponsored by GE HealthCare. Primary endpoint: Maximum peak increase in Serum Creatinine from baseline at Day 3. Planned start Jun 2006; status: withdrawn.
02
Drugs
iodixanol
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00335101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00335101.